Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating reissued by N+1 Singer in a research note issued to investors on Tuesday. They currently have a GBX 208 ($2.60) price target on the stock. N+1 Singer’s price target points to a potential upside of 38.02% from the stock’s current price.

A number of other brokerages have also weighed in on VEC. Peel Hunt restated a “buy” rating and issued a GBX 200 ($2.50) price objective on shares of Vectura Group PLC in a report on Friday, August 5th. Stifel Nicolaus restated a “buy” rating and issued a GBX 242 ($3.02) price objective on shares of Vectura Group PLC in a report on Friday, July 29th. Numis Securities Ltd restated a “buy” rating and issued a GBX 246 ($3.07) price objective on shares of Vectura Group PLC in a report on Thursday, July 28th. FinnCap restated a “buy” rating and issued a GBX 225 ($2.81) price objective on shares of Vectura Group PLC in a report on Tuesday, August 30th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 230 ($2.87) price objective on shares of Vectura Group PLC in a report on Thursday, July 28th. Eight analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of GBX 222.13 ($2.78).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Shares of Vectura Group PLC (LON:VEC) opened at 150.50 on Tuesday. Vectura Group PLC has a 12-month low of GBX 122.90 and a 12-month high of GBX 200.10. The stock’s market capitalization is GBX 617.98 million. The firm has a 50-day moving average of GBX 138.30 and a 200 day moving average of GBX 147.81.

In other Vectura Group PLC news, insider Trevor Phillips sold 240,841 shares of the firm’s stock in a transaction on Tuesday, September 27th. The shares were sold at an average price of GBX 139 ($1.74), for a total transaction of £334,768.99 ($418,252.11). Also, insider Bruno Angelici acquired 80,000 shares of the stock in a transaction on Monday, September 26th. The shares were acquired at an average cost of GBX 143 ($1.79) per share, for a total transaction of £114,400 ($142,928.54).

COPYRIGHT VIOLATION WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and reposted in violation of US & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/vectura-group-plc-vec-stock-rating-reaffirmed-by-n1-singer.html.

Vectura Group PLC Company Profile

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.